ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2: Immunization, Appendix B and Appendix D

Appendix B – Administration of Biological Products

The entire section has been updated and reorganized. Key revisions include:

- Addition of new subsections: Product Reconstitution, Drawing Up a Large Quantity of Biological Product for Individual Use, Syringes Pre-Filled by the Manufacturer, Oral Administration and Intranasal Administration.
- Addition of table summarizing ‘Recommended Needle Sizes, Sites, and Maximum Volumes for Intramuscular Injection’ according to age.
  - For intramuscular (IM) administration of vaccines into the deltoid site for infants, toddlers and older children, the recommended needle length has been revised to 5/8” to 1” as per current evidence. Selection of needle length depends on the muscle size and the amount of subcutaneous tissue, with a needle length sufficient to reach the largest part of the muscle.
- The deltoid is no longer the preferred site for IM injections for toddlers 12 months to 2 years. Either the deltoid or vastus lateralis may be used depending on available muscle mass.
- Rapid injection is no longer recommended for subcutaneous and intramuscular administration of biological products as there is a lack of evidence supporting the effect of rapid injection on reduction of immunization pain.
- All content related to tuberculin skin test (TST) administration has been removed; refer to Chapter 4: Tuberculosis for information related to TST administration.
- Minor revisions have been made to the Acetaminophen and Ibuprofen Dosing Guidelines Tables.
- The reference list has been updated, and in-text citations have been added.

Please remove page numbers: 1 – 26 dated September 2016
Please add new page numbers: 1 – 32 dated December 2018
Appendix D – Reducing Immunization Injection Pain

The entire section has been reorganized and updated based on the “HELPinKids & Adults (expanded and updated): Clinical Practice Guideline for Reducing Pain during Vaccine Injections in Children and Adults”. Key revisions include:

• General:
  o Addition of new subsections: General Considerations, Strategies to Reduce Pain and Anxiety, and Techniques to Reduce the Risk of Fainting.
  o Immunization injection pain reduction strategies are now grouped into age categories, with overarching strategies that are effective with individuals of all ages. Strategies in each group are evidence-based and the interventions reflect best practice in five domains: procedural, physical, pharmacological, psychological, and process.
  o Recommendation for rapid injection has been removed based on lack of supporting evidence for this practice.
  o Recommendation for the use of topical anesthetics has been updated for all age groups, including a recommendation to combine topical anesthetics with other strategies.
  o Removal of the recommendation to consider use of practice dolls due to lack of evidence and feasibility.
  o Information related to the simultaneous administration of vaccines has been revised to reflect evidence for best practice in different age groups.

• Infants and Children < 3 Years of Age
  o Addition of the recommendation for non-breastfeeding infants to be offered either breastmilk alternative or non-nutritive sucking options (e.g., pacifier)
  o Additions to the recommendation for use of sweet-tasting solutions:
    ▪ Expanded age range for use in infants and children up to 2 years of age
    ▪ Information regarding RotaTeq® has been added
  o Addition of the Canadian Pediatric Society recommendation against screen time for children < 2 years of age with regard to the use of videos as a distraction technique.

• Children 3-17 Years of Age:
  o Addition of vibrating devices with cold as a pain reducing strategy
  o The use of a multifaceted approach that includes a vibrating device and cold is recommended.
  o Removal of recommendation to rub/stroke near the injection site prior to immunization for children ≥ 4 years of age due to a lack of evidence and concerns that it may increase the sensation of pain by drawing attention to the site.
• Adults ≥ 18 Years of Age:
  o Addition of vapocoolants and breathing techniques as pain reducing strategies
• The reference list has been updated, and in-text citations have been added.

Please remove page numbers: 1 – 26 dated June 2012
Please add new page numbers: 1 – 26 dated December 2018

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: christine.halpert@bccdc.ca) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health, Population & Public Health Division:

Dr. Mark Tyndall
Executive Medical Director
BC Centre for Disease Control, and
Deputy Provincial Health Officer

Craig Thompson
Director, Immunization

Wendy Trotter
Executive Director,
Public Health Services